[go: up one dir, main page]

WO2009154396A3 - Sustained releasing preparation comprising a crude drug extract for preventing moisturization and controlled release - Google Patents

Sustained releasing preparation comprising a crude drug extract for preventing moisturization and controlled release Download PDF

Info

Publication number
WO2009154396A3
WO2009154396A3 PCT/KR2009/003228 KR2009003228W WO2009154396A3 WO 2009154396 A3 WO2009154396 A3 WO 2009154396A3 KR 2009003228 W KR2009003228 W KR 2009003228W WO 2009154396 A3 WO2009154396 A3 WO 2009154396A3
Authority
WO
WIPO (PCT)
Prior art keywords
crude drug
sustained releasing
controlled release
drug extract
releasing preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/003228
Other languages
French (fr)
Other versions
WO2009154396A2 (en
Inventor
Hee-Joo Kil
Jung-Sik Lee
Je-Kyo Jeong
Gyo-Cheol Gu
Seon-Hwa Jung
Ji-Eun Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHARMAPEX CO Ltd
Original Assignee
PHARMAPEX CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020090053084A external-priority patent/KR20090131256A/en
Application filed by PHARMAPEX CO Ltd filed Critical PHARMAPEX CO Ltd
Priority to CN2009800004796A priority Critical patent/CN101896168A/en
Publication of WO2009154396A2 publication Critical patent/WO2009154396A2/en
Publication of WO2009154396A3 publication Critical patent/WO2009154396A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a sustained releasing preparation comprising a crude drug extract for the moisturizing prevention and controlled release, specifically, the sustained releasing preparation comprising a crude drug extract of Salvia miltiorrhiza Bunge, Panax notoginseng Burk, borneolum etc, and water insoluble macro-molecule and/or sustained releasing carrier, which shows 24-hours routinely releasing effect of drug, and could allow the rapid reach to initial therapeutic region well as maintain the drug concentration within therapeutic region during 24 hours in blood.
PCT/KR2009/003228 2008-06-17 2009-06-16 Sustained releasing preparation comprising a crude drug extract for preventing moisturization and controlled release Ceased WO2009154396A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2009800004796A CN101896168A (en) 2008-06-17 2009-06-16 Sustained-release formulation containing crude drug extracts for preventing moisture increase and controlling release

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2008-0056664 2008-06-17
KR20080056664 2008-06-17
KR1020090053084A KR20090131256A (en) 2008-06-17 2009-06-15 Sustained-release preparations containing herbal extracts for inhibition of moisture content and controlled release rates
KR10-2009-0053084 2009-06-15

Publications (2)

Publication Number Publication Date
WO2009154396A2 WO2009154396A2 (en) 2009-12-23
WO2009154396A3 true WO2009154396A3 (en) 2010-03-25

Family

ID=41434552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/003228 Ceased WO2009154396A2 (en) 2008-06-17 2009-06-16 Sustained releasing preparation comprising a crude drug extract for preventing moisturization and controlled release

Country Status (1)

Country Link
WO (1) WO2009154396A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109044902A (en) * 2018-08-17 2018-12-21 王凡 A kind of lamp-dish flower acetic toothpaste and its application

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1396920B1 (en) * 2009-11-11 2012-12-20 Velleja Res Srl FORMULATIONS INCLUDING CARNOSIS ACID, OR EXTRACTIVE DERIVATIVES THAT CONTAIN IT, FOR THE TREATMENT AND PREVENTION OF HYPERTRIGLICERIDEMIA
WO2011143844A1 (en) * 2010-05-21 2011-11-24 深圳市齐旺投资有限公司 Traditional chinese medicine composition for treating infection of influenza a virus subtype and preparation method thereof
CN102657719A (en) * 2012-04-27 2012-09-12 中国人民解放军第三七一医院 Chinese medicinal preparation for treating hyperlipidemia
CN109602653B (en) * 2018-12-17 2022-01-11 广州市白云区研美化妆品厂 Composition, cosmetic and essence with whitening effect and preparation method thereof
CN112120970B (en) * 2020-09-29 2023-02-03 上海相宜本草化妆品股份有限公司 Chinese herbal medicine essential oil composition with permeation promoting effect, preparation method and application thereof
CN114470508B (en) * 2022-01-26 2023-07-21 中原工学院 A kind of physiotherapy salt pillow material with drug sustained release effect, preparation method and application
CN115501156B (en) * 2022-09-28 2023-12-29 福建片仔癀化妆品有限公司 Cosmetic raw material composition with whitening and soothing effects and evaluation system thereof
CN120242134B (en) * 2025-04-09 2025-11-25 海南觅蜜健康科技有限公司 An antibacterial and protective hydrogel, its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980066045A (en) * 1997-01-18 1998-10-15 이영호 Pure X-dried powder of herbal medicine containing no excipients and preparation method thereof
US20030068369A1 (en) * 2001-01-30 2003-04-10 Mcallister Stephen Mark Pharmaceutical formulation
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980066045A (en) * 1997-01-18 1998-10-15 이영호 Pure X-dried powder of herbal medicine containing no excipients and preparation method thereof
US20030068369A1 (en) * 2001-01-30 2003-04-10 Mcallister Stephen Mark Pharmaceutical formulation
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109044902A (en) * 2018-08-17 2018-12-21 王凡 A kind of lamp-dish flower acetic toothpaste and its application

Also Published As

Publication number Publication date
WO2009154396A2 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
WO2009154396A3 (en) Sustained releasing preparation comprising a crude drug extract for preventing moisturization and controlled release
IL211907A (en) Herbal formulation comprising a combination of herbs, an anticancer composition comprising the formulation and use of the formulation for the preparation of a medicament for use in the prevention and/or treatment of cancer
WO2009148620A3 (en) Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
WO2009034559A3 (en) Cosmetic process for aesthetic and/or repairing treatment of the skin
WO2009125964A3 (en) Composition comprising polysaccharide extracted from panax ginseng preventing and treating liver diseases
WO2010067286A3 (en) IgE CH3 PEPTIDE VACCINE
TN2011000416A1 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
WO2007131677A8 (en) Use of ginsenosides and extracts containing them
IL216599A (en) 1,4-disubstituted phthalazine derivatives, pharmaceutical compositions comprising them and use thereof in the treatment of cancer
WO2009106975A3 (en) Activation of innate and adaptive immune responses by a ginseng extract
WO2009134866A3 (en) Cell membrane engineering
WO2011063178A3 (en) Intravenous infusion of curcumin and a calcium channel blocker
WO2008127302A3 (en) Compositions for treatment and inhibition of pain
WO2011051633A3 (en) Use of a punica granatum extract to fight against the whitening of the hair
WO2011071296A3 (en) Anti-inflammatory pharmaceutical composition comprising extracts from broussonetia papyrifera and lonicera japonica
WO2009028605A1 (en) Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
WO2010127143A3 (en) Neuroprotective ganoderma compositions and methods of use
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity
WO2010019864A3 (en) Ficus extracts having angiogenesis inhibiting activity and methods of isolating and using the same
ATE522224T1 (en) MEDICAL HERBAL EXTRACT WITH ANTI-OBESITY EFFECT
WO2011024168A3 (en) Sustained release delivery systems for the prevention and treatment of head and neck cancers
SG169346A1 (en) Use of yeast flakes for treating and/or preventing hyperinsulinemia

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980000479.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09766821

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09766821

Country of ref document: EP

Kind code of ref document: A2